Novo Nordisk Q4 profit beats expectations, sees slower growth in 2025
Weight-loss and diabetes drugmaker Novo Nordisk on Wednesday posted fourth-quarter operating profit above expectations as it forecast sales to grow at a slower pace in 2025 than last year.
Novo Nordisk's sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024
Bagsværd, 5 February 2025 - Financial report for the period 1 January 2024 to 31 December 2024
Shareholders With Losses In Novo Nordisk A/S Have Opportunity To Lead The Schall Law Firm In A Securities Fraud Case
LOS ANGELES, CA / ACCESS Newswire / February 4, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novo Nordisk A/S ("Nov...
Shareholder Rights Law Firm Robbins LLP Urges NVO Shareholders with Large Losses to Seek Counsel for the Novo Nordisk A/S Class Action
SAN DIEGO , Feb. 4, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Novo Nordisk A/S (NYSE: NVO) s...
Novo Nordisk Stock Slides Before Q4 Earnings: Analysts Still See 68% Upside
Novo Nordisk A/S NVO will report its fourth-quarter earnings on Wednesday. Wall Street expects 86 cents in EPS and $11.40 billion in revenues as the company reports before market hours.
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo Nordisk To Contact Him Directly To Discuss Their Options
Shareholders that lost money on Novo Nordisk A/S(NVO) should contact Levi & Korsinsky about pending Class Action - NVO
NEW YORK , Feb. 4, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit. CLASS DEFINITION: Th...
Focus: Investors seek answers on Novo Nordisk's next-gen obesity drug CagriSema
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a lack of clarity over trial results that hammered its shares in D...
NOVO NORDISK A/S (NYSE: NVO) INVESTOR ALERT: Investors With Large Losses in Novo Nordisk A/S Should Contact Bernstein Liebhard LLP To Discuss Their...
NOVO NORDISK A/S (NYSE: NVO) INVESTOR ALERT: Investors With Large Losses in Novo Nordisk A/S Should Contact Bernstein Liebhard LLP To Discuss Their Rights
Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands
Drugmakers have poured small fortunes into the development of weight loss medicines in the past few years in attempts to lead this lucrative and fast-growing market. However, Novo Nordisk (NVO -1.0...
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 25, 2025 in Novo Nordisk A/S Lawsuit NVO
NEW YORK, NY / ACCESS Newswire / February 1, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities l...
Lost Money on Novo Nordisk A/S(NVO)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / February 1, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities l...
SHAREHOLDER ALERT: Novo Nordisk A/S Is Being Sued For Securities Fraud And Affected Investors Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESS Newswire / February 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novo Nordisk A/S ("Nov...
Novo Nordisk A/S Class Action: Levi & Korsinsky Reminds Novo Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March ...
NEW YORK, NY / ACCESS Newswire / January 31, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities l...
Lowey Dannenberg Notifies Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) Investors of Securities Class Action Lawsuit and Encourages Invest...
NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Nov...
Related Companies